Evaluation of Safety and Immunogenicity of Combined Immunization of PPV23 and IIV4

PHASE4CompletedINTERVENTIONAL
Enrollment

1,224

Participants

Timeline

Start Date

September 11, 2020

Primary Completion Date

November 26, 2020

Study Completion Date

October 9, 2021

Conditions
Influenza, HumanPneumonia, Pneumococcal
Interventions
BIOLOGICAL

IIV4 and PPV23

imultaneously immunization of 23-valent pneumococcal polysaccharide vaccine (PPV23) and quadrivalent inactivated influenza vaccine (IIV4)

BIOLOGICAL

IIV4

administrated with IIV4 only

BIOLOGICAL

PPV23

administrated with PPV23 only

Trial Locations (4)

350001

Liucheng Community Health Services Center, Quanzhou

Unknown

Luodong County Health Center, Quanzhou

Qingzhen Center for Disease Control and Prevention, Qingzhen

Qidong County Center for Disease Control and Prevention, Hongqiao

All Listed Sponsors
collaborator

Center for Disease Control and Prevention, Fujian

OTHER

collaborator

Chengdu Institute of Biological Products Co.,Ltd.

INDUSTRY

collaborator

Changchun Institute of Biological Products Co., Ltd.

INDUSTRY

collaborator

National Institutes for Food and Drug Control, China

OTHER

collaborator

Guizhou Center for Disease Control and Prevention

OTHER

collaborator

Hunan Provincial Center for Disease Control and Prevention

OTHER

collaborator

Peking University

OTHER

lead

China National Biotec Group Company Limited

INDUSTRY

NCT04559204 - Evaluation of Safety and Immunogenicity of Combined Immunization of PPV23 and IIV4 | Biotech Hunter | Biotech Hunter